Evidence map›Paper›PMID 22479438›Full record

ArticlePloS one2012

Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery.

Desmond B S Pink, Wendy Schulte, Missag H Parseghian, Andries Zijlstra, John D Lewis

Abstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse.Journal of visualized experiments : JoVE · 2018
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Techniques and assays for the study of angiogenesis.Experimental biology and medicine (Maywood, N.J.) · 2014
    Review
  15. Review
  16. The chick embryo as an expanding experimental model for cancer and cardiovascular research.Developmental dynamics : an official publication of the American Association of Anatomists · 2014
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Desmond B S PinkInnovascreen, Inc., Halifax, Nova Scotia, Canada.
Wendy Schulte
Missag H Parseghian
Andries Zijlstra
John D Lewis

Funding

The molecular mechanisms of migration of which lead to tumor cell intravasation.K01CA120711 · NCI · VANDERBILT UNIVERSITY · PI ZIJLSTRA, ANDRIES · 2007 to 2011
$719k
NCI NIH HHS #CA120711-01A1NCI NIH HHS K01 CA120711
6 · The paper itself

Abstract

The leaky, heterogeneous vasculature of human tumors prevents the even distribution of systemic drugs within cancer tissues. However, techniques for studying vascular delivery systems in vivo often require complex mammalian models and time-consuming, surgical protocols. The developing chicken embryo is a well-established model for human cancer that is easily accessible for tumor imaging. To assess this model for the in vivo analysis of tumor permeability, human tumors were grown on the chorioallantoic membrane (CAM), a thin vascular membrane which overlays the growing chick embryo. The real-time movement of small fluorescent dextrans through the tumor vasculature and surrounding tissues were used to measure vascular leak within tumor xenografts. Dextran extravasation within tumor sites was selectively enhanced an interleukin-2 (IL-2) peptide fragment or vascular endothelial growth factor (VEGF). VEGF treatment increased vascular leak in the tumor core relative to surrounding normal tissue and increased doxorubicin uptake in human tumor xenografts. This new system easily visualizes vascular permeability changes in vivo and suggests that vascular permeability may be manipulated to improve chemotherapeutic targeting to tumors.

Indexed as

Capillary PermeabilityDrug Delivery SystemsAnimalsCell LineChick EmbryoChorioallantoic MembraneDoxorubicinEvans BlueHumansInterleukin-2MicroscopyNeoplasmsNeovascularization, PathologicTime-Lapse ImagingTransplantation, HeterologousTumor MicroenvironmentDoxorubicinEvans BlueInterleukin-2Vascular Endothelial Growth Factor A

Identifiers

PMID22479438
PMCPMC3315578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.